Abstract:The gp41 subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein plays an important role in HIV-1 entry and severs as an attractive target for development of HIV-1 entry inhibitors, a new class of anti-HIV drugs. Triggered by gp120 binding to CD4 and a coreceptor, gp41 undergoes a conformation shift from a native prefusogenic state to a fusogenic state, in which the N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR) associate to form a six-helix bundle, representing the fusion-active gp41 core. Any compound that disrupts the gp41 six-helix bundle formation may inhibit the gp41-mediated membrane fusion, thereby blocking HIV-1 entry into target cells. Peptides derived from the gp41 NHR and CHR regions, designated N- and C-peptides, can interact with the counterpart regions in gp41 and interfere with the six-helix bundle formation between the viral NHR and CHR region, thus inhibiting fusion of the virus with the target cell. One of the C-peptides, T-20 (brand name: Fuzeon), was recently approved by the US FDA as the first HIV entry inhibitor which can be used for treatment of AIDS patients who fail to respond to the current antiretroviral drugs, e.g., the reverse transcriptase inhibitors and protease inhibitors. The limitations of T-20 include lack of oral availability and high cost of production. Thus it is essential to develop small molecule HIV-1 entry inhibitors targeting gp41. This review summarizes the newly developed techniques for high throughput screening (I-ITS) and characterization of the HIV-1 entry inhibitors targeting gp41. The theories behind these techniques are also discussed. It is expected that the "drug-like" compounds with potent HIV-1 fusion inhibitory activity will be identified in the near future and used as leads for development of the low molecular weight HIV-1 entry inhibitors for the chemotherapy of HIV-1 infection and AIDS.

A Screening Assay for Antiviral Compounds Targeted to the HIV-1 Gp41 Core Structure Using a Conformation-Specific Monoclonal Antibody

Rapid and Automated Fluorescence-Linked Immunosorbent Assay for High-Throughput Screening of Hiv-1 Fusion Inhibitors Targeting Gp41

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Structure-Based Identification of Small Molecule Antiviral Compounds Targeted to the Gp41 Core Structure of the Human Immunodeficiency Virus Type 1

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

Development of a Cell-Based Enzyme-Linked Immunosorbent Assay for High-Throughput Screening of HIV Type 1 Entry Inhibitors Targeting the Coreceptor CXCR4.

Screening HIV-1 Fusion Inhibitors Based on Capillary Electrophoresis Head-End Microreactor Targeting to the Core Structure of Gp41

Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors.

Study of the Cyclic Peptide Binding to HIV-1 Gp41 NHR

[Virtual Screening of Small Molecular HIV-1 Entry Inhibitor NC-2 Targeting Gp120 and Its Action Mechanism].

ADS-J 1 Inhibits Human Immunodeficiency Virus Type 1 Entry by Interacting with the Gp 41 Pocket Region and Blocking Fusion-Active Gp 41 Core Formation

High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting Gp41: Theories and Techniques.

[A Non-Infectious and Quantitative Cell-Based Bioassay for Screening HIV Entry Inhibitors Targeting HIV Envelope Proteins].

Rapid Prescreening for Antiviral Agents against HIV-1 Based on Their Inhibitory Activity in Site-Directed Immunoassays. Approaches Applicable to Epidemic HIV-1 Strains

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

A Salt Bridge Between An N-Terminal Coiled Coil Of Gp41 And An Antiviral Agent Targeted To The Gp41 Cove Is Important For Anti-Hiv-1 Activity

Application of an NMR/crystallography fragment screening platform for the assessment and rapid discovery of new HIV‐CA binding fragments

Engineering And Functional Evaluation Of A Single-Chain Antibody Against Hiv-1 External Glycoprotein Gp120

Identification of the HIV-1 gp41 core-binding motif--HXXNPF.